Newsletter registration

By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Your Profits Grow Sky High.

Hookipa: EUR 50 million for immunotherapy against cancer

© Hookipa Biotech

A vaccination against the Cytomegalovirus ("CMV"), which is a herpesvirus, should be tested on patients undergoing organ transplants. In addition, immunization therapy is to be tested on patients with head and neck squamous cell carcinoma. Founded in 2011, the company develops active immunotherapies against cancer and infectious diseases. The new investors include a blue-chip U.S. public investment fund as well as HBM Partners, Hillhouse Capital, Sirona Capital and the strategic investor Gilead. The existing investors of Hookipa, namely Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners, also participated in the financing. An infection with CMV is harmless for healthy people, but can be deadly for people with weakened immune systems, especially following organ transplants. An infection during pregnancy can also have fatal consequences for the baby.Founded in 2011, the company develops active immunotherapies against cancer and infectious diseases. The new investors include a blue-chip U.S. public investment fund as well as HBM Partners, Hillhouse Capital, Sirona Capital and the strategic investor Gilead. The existing investors of Hookipa, namely Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners, also participated in the financing. An infection with CMV is harmless for healthy people, but can be deadly for people with weakened immune systems, especially following organ transplants. An infection during pregnancy can also have fatal consequences for the baby.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Doing Business in Austria

    03.03.2020, Bratislava, Slovakia

  • Austria as a European window for Russian export opportunities

    05.03.2020, Moscow, Russia

Austria Map

Find the perfect location for your company

Thanks to a fantastic mindset, our employees at the Villach site have built up a unique expertise which helps us to further strengthen our position on the global market. We fuse high-performance manufacturing with research and development in the field of power electronics. In addition to a very good cooperation with partners and networks, a well-developed landscape of 'talent factories' ranging from higher technical colleges to universities, we as a company also value the outstanding model of research promotion which exists in Austria.

Infineon

Logo Infineon
More testimonials

news from the business location Austria

Many-body quantum physics

Many of the biggest questions in physics can be answered with the help of quantum field theories: They are needed to describe the dynamics of many interacting particles. These theories are just as essential in solid state physics as they are in cosmology.

Growing demand for natural active ingredients enables Phytovalley Tyrol to flourish

The comeback of plant-based active ingredients in medicine, cosmetics and food production has positive impacts on Tyrol as a business location. Austria has succeeded in playing a pioneering role in plant research thanks to the support of the federal government, the Federal Province of Tyrol, the company Bionorica and the University of Innsbruck. This niche in plant research already established itself in Innsbruck years ago.

More news All blog posts